共查询到20条相似文献,搜索用时 15 毫秒
1.
Transfemoral valve‐in‐valve implantation for degenerated bioprosthetic aortic valves using the new balloon‐expandable Edwards Sapien 3 valve 下载免费PDF全文
Birgid Gonska MD Julia Seeger MD Christoph Rodewald MD Dominik Scharnbeck MD Wolfgang Rottbauer MD Jochen Wöhrle MD 《Catheterization and cardiovascular interventions》2016,88(4):636-643
2.
Outcome of paravalvular leak repair after transcatheter aortic valve replacement with a balloon‐expandable prosthesis 下载免费PDF全文
Abhijeet Dhoble MD Tarun Chakravarty MD Mamoo Nakamura MD Yigal Abramowitz MD Rikin Tank MD Hirotsugu Mihara MD Geeteshwar Mangat MD Hasan Jilaihawi MD Takahiro Shiota MD Raj Makkar MD 《Catheterization and cardiovascular interventions》2017,89(3):462-468
3.
4.
Bradley C. Nelson Scott Chadderdon Howard Song Firas E. Zahr 《Catheterization and cardiovascular interventions》2019,93(1):164-168
Transcatheter aortic valve replacement (TAVR) is well‐established for the treatment of bioprosthetic aortic valve stenosis (AS) in high surgical risk patients. Coronary artery obstruction from displacement of the bioprosthetic valve leaflets during valve‐in‐valve (VIV) TAVR is a rare, but potentially fatal, complication. Recently, the bioprosthetic aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (BASILICA) procedure was developed as a method for disrupting bioprosthetic leaflets in patients undergoing VIV TAVR at high risk for coronary obstruction. This case describes a successful VIV TAVR utilizing a simplified concept of the BASILICA technique in a patient where the full procedure could not be completed. 相似文献
5.
6.
7.
Santiago Garcia Mackenzie Mbai Rosemary Kelly Stefan Bertog 《Catheterization and cardiovascular interventions》2019,93(3):559-561
In patients with an Alfieri Stitch transcatheter mitral valve replacement (TMVR) may be difficult due to the double orifice configuration of the mitral valve. We report a case of simultaneous and completely percutaneous TAVR and TMVR using LAMPOON‐related techniques prior to TMVR to allow for optimal valve deployment. 相似文献
8.
Vladislavs Sokalskis MD Denisa Muraru MD PhD Chiara Fraccaro MD PhD Massimo Napodano MD Augusto D'Onofrio MD PhD Giuseppe Tarantini MD PhD Luigi Paolo Badano MD PhD 《Echocardiography (Mount Kisco, N.Y.)》2017,34(2):267-278
The use of transcatheter aortic valve replacement (TAVR) for high‐risk patients with aortic stenosis has rapidly increased during the past years. Accordingly, more and more patients are referred for a follow‐up echocardiographic study after TAVR. However, the echocardiographic evaluation of patients who underwent TAVR places specific demands on echocardiographers. Furthermore, TAVR may be associated with new types of complications, which are frequently unrecognized or underestimated due to lack of familiarity with the normal and pathological appearance of TAVR. Therefore, this review summarizes the echocardiographic parameters describing the structural and functional status of bioprostheses used in TAVR, procedures taking into account their peculiar hemodynamics. We also describe the strengths and the limitations of echocardiography and of other imaging modalities in detecting long‐term complications of TAVR (eg, infective endocarditis, thrombosis). The aim of this review was to serve as a guide for a structured echocardiographic follow‐up of TAVR patients, as well as for the echocardiographic diagnosis of the procedure‐associated complications. 相似文献
9.
Reversible thrombotic aortic valve restenosis after valve‐in‐valve transcatheter aortic valve replacement 下载免费PDF全文
Patrick J. Goleski MD Mark Reisman MD Creighton W. Don MD 《Catheterization and cardiovascular interventions》2018,91(1):165-168
Thrombotic aortic valve restenosis following transcatheter aortic valve replacement (TAVR) has not been extensively reported and the rates of TAVR valve thrombosis are not known. We present three cases of valve‐in‐valve (VIV) restenosis following TAVR with the balloon expandable transcatheter heart valves, presumably due to valve thrombosis that improved with anticoagulation. © 2016 Wiley Periodicals, Inc. 相似文献
10.
11.
The impact of frailty status on clinical and functional outcomes after transcatheter aortic valve replacement in nonagenarians with severe aortic stenosis 下载免费PDF全文
Alexis K. Okoh MD Dhaval Chauhan MD Nathan Kang MS Nicky Haik BA Aurelie Merlo BA Mark Cohen MD Bruce Haik MD Chunguang Chen MD Mark J. Russo MD MS 《Catheterization and cardiovascular interventions》2017,90(6):1000-1006
12.
Alison Duncan Saeed Mirsadraee Cesare Quarto Simon Davies 《Catheterization and cardiovascular interventions》2020,96(1):228-235
Valve‐in‐valve transcatheter aortic valve implantation (ViV‐TAVI) is an established therapy for a degenerated surgical bioprosthesis. TAVI‐in‐TAVI following ViV‐TAVI has not been previously performed. We report a high‐risk patient presenting with severe left ventricular failure secondary to undiagnosed critical aortic stenosis due to degeneration of the implanted transcatheter heart valve more than a decade after initial ViV‐TAVI for a failing stentless aortic valve homograft. Successful TAVI‐in‐TAVI reversed the clinical and echocardiographic changes of decompensated heart failure with no evidence of coronary obstruction. 相似文献
13.
The impact of mitral stenosis on outcomes of aortic valve stenosis patient undergoing surgical aortic valve replacement or transcatheter aortic valve replacement 下载免费PDF全文
Yasser Al‐khadra MD Fahed Darmoch MD Motaz Baibars MD Amir Kaki MD Zaher Fanari MD M. Chadi Alraies MD 《Journal of interventional cardiology》2018,31(5):655-660
Background
The concomitant presence of mitral stenosis (MS) in the setting of symptomatic aortic stenosis represent a clinical challenge. Little is known regarding the outcome of mitral stenosis (MS) patients undergoing transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). Therefore, we sought to study the outcome of MS patients undergoing aortic valve replacement (AVR).Method
Using weighted data from the National Inpatient Sample (NIS) database between 2011 and 2014, we identified patients who were diagnosed with MS. Patients who had undergone TAVR as a primary procedure were identified and compared to patients who had SAVR. Univariate and multivariate logistic regression analysis were performed for the outcomes of in‐hospital mortality, length of stay (LOS), blood transfusion, postprocedural hemorrhage, vascular, cardiac and respiratory complications, permanent pacemaker placement (PPM), postprocedural stroke, acute kidney injury (AKI), and discharge to an outside facility.Results
A total of 4524 patients were diagnosed with MS, of which 552 (12.2%) had TAVR and 3972 (87.8%) had SAVR. TAVR patients were older (79.9 vs 70.0) with more females (67.4% vs 60.0%) and African American patients (7.7% vs 7.1%) (P < 0.001). In addition, the TAVR group had more comorbidities compared to SAVR in term of coronary artery disease (CAD), congestive heart failure (CHF), chronic lung disease, hypertension (HTN), chronic kidney disease (CKD), and peripheral vascular disease (PVD) (P < 0.001 for all). Using Multivariate logistic regression, and after adjusting for potential risk factors, TAVR patients had lower in‐hospital mortality (7.9% vs 8.1% adjusted Odds Ratio [aOR], 0.615; 95% confidence interval [CI], 0.392–0.964, P = 0.034), shorter LOS. Also, TAVR patients had lower rates of cardiac and respiratory complications, PPM, AKI, and discharge to an outside facility compared with the SAVR group.Conclusion
In patients with severe aortic stenosis and concomitant mitral stenosis, TAVR is a safe and attractive option for patients undergoing AVR with less complications compared with SAVR.14.
Aortic root volume is associated with contained rupture of the aortic annulus in balloon‐expandable transcatheter aortic valve replacement 下载免费PDF全文
Jochen Reinöhl MD Dimitrios Psyrakis MD Klaus Kaier PhD Sodikdjon Kodirov PhD Matthias Siepe MD Anja Gutmann MD Constantin von zur Mühlen MD Martin Moser MD Ingo Ahrens MD Gregor Pache MD Andreas Zirlik MD Mathias Langer MD Friedhelm Beyersdorf MD Manfred Zehender MD PhD Christoph Bode MD Philipp Blanke MD 《Catheterization and cardiovascular interventions》2016,87(4):807-817
15.
Marco Hernndez‐Enríquez Ander Regueiro Rafael Romaguera Rut Andrea Joan Antoni Gmez‐Hospital Margarida Pujol‐Lpez Jos Luis Ferreiro‐Gutirrez Salvatore Brugaletta Gerard Roura Xavier Freixa Josep Gmez‐Lara Victoria Martín‐Yuste Montserrat Gracida ngel Cequier Manel Sabat 《Catheterization and cardiovascular interventions》2019,93(7):1344-1351
16.
17.
Major thrombocytopenia after balloon‐expandable transcatheter aortic valve replacement: Prognostic implications and comparison to surgical aortic valve replacement 下载免费PDF全文
Hasan Jilaihawi MD Niraj Doctor MD Tarun Chakravarty MD Mohammad Kashif MD James Mirocha MD Wen Cheng MD Michael Lill MD Mamoo Nakamura MD Mitch Gheorghiu MD Raj R. Makkar MD 《Catheterization and cardiovascular interventions》2015,85(1):130-137
18.
Ronen Gurvitch MBBS Anson Cheung MD Francesco Bedogni MD John G. Webb MD 《Catheterization and cardiovascular interventions》2011,77(3):439-444
Transcatheter aortic valve implantation (TAVI) for failed surgical bioprostheses, or “valve‐in‐valve” implantation, is a therapeutic option for high‐risk patients. While coronary occlusion during TAVI for native aortic stenosis has been described, in the setting of valve‐in‐valve implantation the bioprsthetic posts may be protective against this complication. We describe the first two cases of coronary occlusion following valve‐in‐valve therapy, both occurring during treatment of degenerated Mitroflow bioprostheses. Aortic root anatomy, coronary ostial position, and the specifics of the bioprosthetic valve type need to be considered in assessing and preventing this rare complication. © 2011 Wiley‐Liss, Inc. 相似文献
19.
Prognostic value of aortic root calcification volume on clinical outcomes after transcatheter balloon‐expandable aortic valve implantation 下载免费PDF全文
Yusuke Watanabe MD Thierry Lefèvre MD FESC FSCAI Erik Bouvier MD Takahide Arai MD PhD Kentaro Hayashida MD PhD FESC Bernard Chevalier MD FESC FACC FSCAI Mauro Romano MD Thomas Hovasse MD Philippe Garot MD FESC Patrick Donzeau‐Gouge MD Arnaud Farge MD Bertrand Cormier MD Marie‐Claude Morice MD FESC FACC 《Catheterization and cardiovascular interventions》2015,86(6):1105-1113
20.
Contemporary transcatheter aortic valve replacement with third‐generation balloon‐expandable versus self‐expanding devices 下载免费PDF全文
Toby Rogers MD PhD Arie Steinvil MD Kyle Buchanan MD M. Chadi Alraies MD Edward Koifman MD Jiaxiang Gai MSPH Rebecca Torguson MPH Petros Okubagzi MD Itsik Ben‐Dor MD Augusto Pichard MD Lowell Satler MD Ron Waksman MD 《Journal of interventional cardiology》2017,30(4):356-361